Lori J. Wirth, MD, discusses the role of lenvatinib in the treatment landscape of differentiated thyroid cancer and how this might evolve in the future.
Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses the role of lenvatinib (Lenvima) in the treatment landscape of differentiated thyroid cancer and how this might evolve in the future.
Wirth believes that lenvatinib will remain the standard of care in this patient population for a long time. She says it is hard to beat an overall response rate of 65% and progression-free survival benefit of 15 months. Lenvatinib has set the bar high for treatment of these patients.
Smaller studies have looked at approaches to targeting mutations in these patients, but the data have not yet shown similar responses compared to lenvatinib.